3 completed, 3 terminated, 2 active not recruiting, 2 recruiting. 11 Phase 2, 7 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 3, Terminated 3, Active not recruiting 2, Recruiting 2, Withdrawn 1 |
| Phase 1 | 7 | Completed 3, Active not recruiting 2, Terminated 2 |
| Phase 3 | 1 | Recruiting 1 |
Follow cedazuridine: new trials by email Literature Review of cedazuridine trials Research Report on cedazuridine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET, Ivosidenib Oral Tablet, Hydroxyurea - Acute Myeloid Leukemia With Gene Mutations | Phase 2 | Recruiting | PETHEMA Foundation | 50 | 2026-06-12 | 2026-11-17 |
| Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes KPT-8602, Inqovi, Bone marrow aspirate - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 3 | 2023-11-14 | 2025-12-02 |
| PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes IV Decitabine, Decitabine and cedazuridine, only Decitabine and cedazuridine - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Active not recruiting | Otsuka Beijing Research Institute | 72 | 2023-10-16 | 2026-10-16 |
| Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients Who Have Relapsed Acute Myeloid Leukemia After Donor Stem Cell Transplant Venetoclax, Decitabine, Cedazuridine - Recurrent Acute Myeloid Leukemia | Phase 2 | Terminated | Sanjay Mohan | 1 | 2023-04-13 | 2026-01-09 |
| BMS-986253 in Myelodysplastic Syndromes Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine, Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine, BMS-986253 - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2022-11-29 | 2025-09-30 |
| Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab - Malignant Melanoma | Phase 1 / Phase 2 | Completed | University of Colorado, Denver | 8 | 2022-06-20 | 2026-11-09 |
| A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes Pevonedistat, Decitabine, Cedazuridine - Myelodysplastic Syndromes (MDS) | Phase 2 | Withdrawn | Takeda | 2021-10-01 | 2021-09-29 | |
| Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) Decitabine and Cedazuridine (ASTX727), Venetoclax - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Active not recruiting | Taiho Oncology, Inc. | 101 | 2021-02-09 | 2026-10-06 |
| A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) Azacitidine, ASTX030 (cedazuridine + azacitidine), Cedazuridine - Myelodysplastic Syndromes, Acute Myeloid Leukemia | Phase 2 / Phase 3 | Recruiting | Taiho Oncology, Inc. | 316 | 2020-05-21 | 2026-10-06 |
| Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS ASTX727 LD, ASTX727 SD - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Completed | Taiho Oncology, Inc. | 160 | 2018-07-27 | 2026-04-03 |
| Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) ASTX727 Dose Escalation, ASTX727 Dose Confirmation, ASTX727 Fixed-Dose Combination - Myelodysplastic Syndrome, MDS | Phase 1 / Phase 2 | Completed | Astex Pharmaceuticals, Inc. | 130 | 2014-10-28 | 2024-08-27 |
Myelodysplastic Syndromes (7) · Leukemia, Myeloid, Acute (4) · Anemia, Refractory, with Excess of Blasts (1) · Cytopenia (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, Myelomonocytic, Chronic (1) · Melanoma (1)
Taiho Oncology, Inc. (3) · National Cancer Institute (NCI) (2) · Astex Pharmaceuticals, Inc. (1) · Otsuka Beijing Research Institute (1) · PETHEMA Foundation (1) · Sanjay Mohan (1) · Takeda (1) · University of Colorado, Denver (1)
United States (8) · Canada (4) · Spain (4) · Germany (2) · Italy (2) · Belgium (1) · China (1) · Czechia (1) · France (1) · Hungary (1) · Poland (1) · Portugal (1) · United Kingdom (1)
Najla El Jurdi, M.D. (2) · James Lowder, MD (1) · Martin McCarter (1) · Mohammad Azab, MD (1) · Pau Montesinos (1) · Sanjay Mohan, MD (1)